Elina Molou
Papers
1
Total Citations
17
H-Index
1
About
Elina Molou is a clinical pharmacologist and molecular biologist whose research focuses on the interplay between genetic polymorphisms and drug metabolism, particularly in the context of proton pump inhibitors. Her most-cited work investigates how CYP2C19 genetic variants influence the pharmacokinetics of omeprazole, a widely prescribed acid-reducing medication. In this study, she employed a validated LC–MS/MS method alongside Real Time-PCR to precisely quantify drug levels and genotype patients, demonstrating that CYP2C19 poor metabolizers exhibit significantly higher omeprazole exposure. This contribution has direct implications for personalized dosing strategies, helping to optimize therapeutic efficacy and minimize adverse effects in diverse populations. With 17 citations, her paper has informed subsequent research on genotype-guided prescribing in gastroenterology. Molou’s work bridges analytical chemistry and clinical genetics, showcasing a rigorous approach to pharmacogenomics. Her findings underscore the importance of integrating genetic testing into routine clinical practice, particularly for drugs with narrow therapeutic windows. For students and researchers, Molou exemplifies how targeted, methodologically sound studies can translate into actionable insights for precision medicine.
Research Focus
Key Achievements
Top Papers
- 1